Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Semaglutide

Knowing that you are interested in Semaglutide, we have listed articles on similar topics on the website for your convenience. As a professional manufacturer, we hope that this news can help you. If you are interested in learning more about the product, please feel free to contact us.
  • Unibest Unveils Innovative 505(b)(2) Project for Semaglutide: UB104

    2025-04-16

    In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 24 2025

    2025-03-24

    This week, there are 10 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - NALPROPION PHARMACEUTICALS LLC's CONTRAVE, containing active ingredient BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - WYETH PHARMACEUTICALS LLC's PROTONIX, containing active ingredient PANTOPRAZOLE SODIUM - PURDUE PHARMA LP's OXYCONTIN, containing active ingredient OXYCODONE HYDROCHLORIDE - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - BRISTOL MYERS SQUIBB CO's ZEPOSIA, containing active ingredient OZANIMOD HYDROCHLORIDE - VERITY PHARMACEUTICALS INC's TLANDO, containing active ingredient TESTOSTERONE UNDECANOATE - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - VIIV HEALTHCARE CO's VOCABRIA, containing active ingredient CABOTEGRAVIR SODIUM Read More
  • Semaglutide: A Promising Frontier in Alzheimer's Disease Prevention

    2024-10-25

    We're excited to discuss groundbreaking research on semaglutide, the blockbuster medication that's showing promising potential in the fight against Alzheimer's disease (AD) Read More
  • Cardiovascular Benefits of Semaglutide - Clinical Trial Interpretation

    2024-07-23

    A recent study published in the international journal Diabetes Care, titled "Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT," has revealed a new benefit of Semaglutide - the cardiovascular benefits. Read More
  • Drug Briefing: Semaglutide

    2024-04-11

    Query Drug:SemaglutideQuery Time:2024-08-26 09:30:00*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest Read More
  • Peptide 101: A Deep Dive into Peptide Drug Market, Development Timeline, and Strategies in Delivery

    2024-01-18

    While everything from dietary changes to high-cost surgeries has been explored to combat diseases, therapeutics derived from peptides have risen as a powerful strategy. Over the past few years, peptide drugs have swept through the pharmaceutical market, redefining treatment approaches for various di Read More